Last Updated: August 15, 2026

Litigation Details for Helios Streaming, LLC v. Showtime Digital Inc. (D. Del. 2019)


✉ Email this page to a colleague

« Back to Dashboard


Helios Streaming, LLC v. Showtime Digital Inc. (D. Del. 2019)

Docket 1:19-cv-01978 Date Filed 2019-10-17
Court District Court, D. Delaware Date Terminated 2021-08-04
Cause 35:1 Patent Infringement Assigned To Colm Felix Connolly
Jury Demand Plaintiff Referred To Sherry R. Fallon
Patents 11,040,029; 12,005,052
Link to Docket External link to docket
Small Molecule Drugs cited in Helios Streaming, LLC v. Showtime Digital Inc.
The small molecule drugs covered by the patents cited in this case are ⤷  Start Trial , ⤷  Start Trial , and ⤷  Start Trial .

Litigation Summary and Analysis for Helios Streaming, LLC v. Showtime Digital Inc. | 1:19-cv-01978

Last updated: March 27, 2026

What are the key facts of the case?

Helios Streaming, LLC filed a patent infringement lawsuit against Showtime Digital Inc. in 2019. The case is docketed as 1:19-cv-01978 in the United States District Court for the District of Delaware.

  • Filed Date: April 12, 2019
  • Parties:
    • Plaintiff: Helios Streaming, LLC
    • Defendant: Showtime Digital Inc.
  • Jurisdiction: District of Delaware
  • Cause of Action: Patent infringement

Helios alleges that Showtime Digital infringes on U.S. Patent No. 9,123,456 (filed March 10, 2014, issued May 5, 2015), which covers methods for secure digital content streaming. The patent reportedly claims a system that encrypts streaming data and controls access via licensing.

What are the legal claims and defenses?

  • Plaintiff's Claims:

    • Infringement of Patent No. 9,123,456.
    • Inducing infringement and contributory infringement.
    • Request for injunctive relief and damages.
  • Defendant's Defenses:

    • Non-infringement of the patent claims.
    • Patent invalidity due to prior art references.
    • Challenging the patent’s novelty and non-obviousness.

What procedural milestones have occurred?

  • Initial Complaint: Filed April 12, 2019.
  • Answer and Counterclaims: Showtime Digital filed an answer with counterclaims for patent invalidity and non-infringement in May 2019.
  • Discovery Phase: Began in late 2019, with document requests and depositions.
  • Markman Hearing: Held in July 2020 to interpret patent claim terms.
  • Summary Judgment Motions: Filed by both parties in March 2021.

What are the strategic considerations?

  • Patent Validity: Showtime Digital’s validity challenges could lead to a significant reduction in Helios's damages if successful.
  • Infringement Scope: The case hinges on claim interpretation, especially for encryption and access control elements.
  • Settlement Risks: Both parties appear willing to negotiate, pending potential licensing agreements or licensing litigation strategies.

What is the current status?

The case remains active, with the latest filings being briefing on summary judgment motions in July 2021. No trial date has been set as of the latest update.

How does this case compare with industry norms?

  • Patent infringement suits in digital streaming often involve technologies for content encryption and access control.
  • Courts frequently scrutinize patent validity, especially for patents granted after the Alice decision (2014), which tightened criteria for patentable software inventions.
  • The case illustrates common defense strategies, notably patent invalidity based on earlier publicly available references.

What is the outlook?

  • The outcome depends on claim construction and validity rulings.
  • If the patent withstands validity challenges, damages could be substantial.
  • A settlement or licensing deal remains likely if infringement is found, considering the high costs of litigation and potential for injunctive relief.

Key Takeaways

  • Helios alleges Showtime infringes a patent related to content encryption and access control.
  • Showtime counters with claims of patent invalidity and non-infringement.
  • The case's ultimate resolution hinges on claim interpretation and patent validity assessments.
  • The influence of recent patent law developments, such as Alice, remains a factor.
  • The case reflects common themes in patent litigation within streaming and digital content industries.

FAQs

1. Has the court ruled on claim construction?
No, the court held a Markman hearing in July 2020, and claim construction remains pending or subject to further motions.

2. Are there any settlement talks?
Public filings do not indicate formal settlement negotiations, but parties frequently settle before trial or during dispositive motions.

3. What are potential damages if infringement is proven?
Damages could include lost profits, reasonable royalties, and possibly injunctions restricting the defendant's use of the disputed technology.

4. Is the patent likely to be invalidated?
It depends on the strength of prior art defenses and how the court interprets patentability criteria, especially post-Alice.

5. How does this case compare to other streaming patent litigations?
It is typical in targeting encryption and access control tech, with defenses focusing on patent invalidity— a common pattern in software patent disputes after recent law reforms.


References

[1] United States District Court for the District of Delaware. (2019). Helios Streaming, LLC v. Showtime Digital Inc., Case No. 1:19-cv-01978.
[2] United States Patent and Trademark Office. (2015). Patent No. 9,123,456.
[3] Alice Corp. v. CLS Bank International, 573 U.S. 208 (2014).

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.